SCHEMBL5545696

SCHEMBL5545696

[CH2]CCCCN(C)C(=O)OCCC

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.39
CHRNA4 P43681 3/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
ALDH1A1 P00352 2/20 0.35
DNM1 Q05193 1/20 0.34
EPHX2 P34913 3/20 0.33
LMNA P02545 2/20 0.32
TSHR P16473 2/20 0.32
HPGD P15428 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
BCHE P06276 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544092 0.98 CHRNB2 (0.38) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5540457 0.95 CHRNB2 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5546059 0.87 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5546237 0.85 CA12 (0.35) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5547671 0.84 LMNA (0.36) CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1
SCHEMBL26832634 0.81 CHRNB2 (0.48) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL18125070 0.81 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5535643 0.79 CA12 (0.36) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL11785064 0.79 NAAA (0.48) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2
SCHEMBL5542893 0.79 CHRNB2 (0.39) CHRNB2CHRNA4CHRNB4CHRNA3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CHRNB2 1140/4885CHRNA4 1505/4885CHRNB4 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.